김준범 교수

논문

• 특허
  1. TRAM-34를 함유하는 화상 후 비후성 피부 흉터 형성 예방용 약학 조성물. 특허 등록번호 제10-1947277호
  2. 레스베라트롤을 함유하는 III형 고셔병 치료용 약학 조성물. 특허 등록번호 제10-1658357호
  3. 칼펩틴을 함유하는 화상 후 비후성 피부 흉터 형성 예방용 약학 조성물. 특허 등록번호 제10-2646259호
  4. 칼파스타틴을 함유하는 화상 후 비후성 반흔 형성 예방용 약학 조성물. 특허 출원번호 제10-2021-0084657호
  5. PD150606을 함유하는 화상 후 비후성 반흔 형성 예방용 약학 조성물. 특허 등록번호 제10-2648325호
  
  수행 연구과제
  1. 교육부 주관 한국연구재단 학문균형발전 사업: 당뇨병 치료제의 항섬유화 효과 및 작용 기전 규명 연구 (연구책임자).
  2. 교육부 주관 한국연구재단 기본연구지원 사업: 이온채널을 표적으로 하는 비후성 반흔 치료제 개발 연구 (연구책임자).
  3. 보건산업진흥원 질병중심 중개연구 중점연구 사업: 유전성 마비 질환 환자들에서 골다공증을 포함한 골대사 질환의 발생 현황과 원인 규명 연구 (연구책임자).
  4. 대한소아과학회 학술연구지원 사업: 가족성 저칼륨성 주기성마비에서 저칼륨혈증의 발생기전에 관한 연구 (연구책임자).
  5. 보건산업진흥원 질병중심 중개연구 기반연구 사업: 폴리페놀을 이용한 고셔병 신경병증 치료제 개발 연구 (연구책임자).
  6. 미래창조과학부 주관 한국학술진흥재단 신진연구지원 사업: 저칼륨성 주기성마비를 유발하는 이온채널병의 원인 유전자 규명 연구 (연구책임자).
  
  대표 논문
  Anti-fibrotic effects of evogliptin in fibroblasts derived from post-burn hypertrophic scars. Scientific Reports 2026; 16: 27592.
  
  Activation of Cannabinoid Receptor 1 Enhances Wound Healing by Promoting the Proliferative Phase. International Journal of Molecular Sciences 2026; 27: 1171.
  
  Prevalence and risk factors of low vitamin D levels in children and adolescents with familial hypokalemic periodic paralysis. European Journal of Pediatrics 2024; 183: 305-311.
  
  Knockdown of CPEB1 and CPEB4 Inhibits Scar Formation via Modulation of TAK1 and SMAD Signaling. Annals of Dermatology 2023; 35: 293-302.
  
  Exosomes derived from human hypertrophic scar fibroblasts induces smad and TAK1 signaling in normal dermal fibroblasts. Archives of Biochemistry and Biophysics 2022; 722: 109215.
  
  Altered KCa3.1 expression following burn injury and the therapeutic potential of TRAM-34 in post-burn hypertrophic scar formation. Translational Research 2021; 236: 133-146.
  
  Calpastatin-mediated inhibition of calpain ameliorates skin scar formation after burn Injury. International Journal of Molecular Sciences 2021; 22: 5771.
  
  Effect of extracorporeal shock wave therapy on keratinocytes derived from human hypertrophic scars. Scientific Reports 2021; 11: 17296.
  
  Effect of combining low temperature plasma, negative pressure wound therapy, and bone marrow mesenchymal stem cells on an acute skin wound healing mouse model. International Journal of Molecular Sciences 2020; 21: 3675.
  
  CPEB1 or CPEB4 knockdown suppresses the TAK1 and Smad signalings in THP-1 macrophage-like cells and dermal fibroblasts. Archives of Biochemistry and Biophysics 2020; 683: 108322.
  
  Wound healing potential of low temperature plasma in human primary epidermal keratinocytes. Tissue Engineering and Regenerative Medicine 2019; 16: 585-593.
  
  Effect of cold pack therapy for management of burn scar pruritus: A pilot study. Burns 2018; 44: 1005-1010.
  
  Extracorporeal shock wave therapy alters the expression of fibrosis-related molecules in fibroblast derived from human hypertrophic scar. International Journal of Molecular Sciences 2018; 19: 124-140.
  
  Low temperature plasma induces angiogenic growth factor via up-regulating hypoxia-inducible factor 1α in human dermal fibroblasts. Archives of Biochemistry and Biophysics 2017; 630: 9-17.
  
  Effects of sustained release growth hormone treatment during the rehabilitation of adult severe burn survivors. Growth Hormone & IGF Research 2016; 27: 1-6.
  
  Effectiveness of Wound Healing using the Novel Collagen Dermal Substitute INSUREGRAF®. RSC Advances 2016; 6: 59692-701.
  
  Therapeutic Potential of Resveratrol in Type I Gaucher Disease. Phytotherapy Research 2015; 29: 835-9.
  
  Anti-apoptotic and Beneficial Metabolic Activities of Resveratrol in Type II Gaucher Disease. Biological and Pharmaceutical Bulletin 2015; 38: 913-8.
  
  Therapeutic potential of resveratrol for the treatment of type III Gaucher disease. Neurology Asia 2015; 20: 43-8.
  
  The large conductance calcium-activated potassium channel holds the key to the conundrum of familial hypokalemic periodic paralysis. Korean Journal of Pediatrics 2014; 57: 445-50.
  
  Channelopathies. Review. Korean Journal of Pediatrics 2014; 57: 1-18.
  
  Cell cycle arrest in Batten disease lymphoblast cells. Gene 2013; 519: 245-50.
  
  Myxobacterial metabolites enhance cell proliferation and reduce intracellular stress in cells from a Parkinson's disease mouse model. Gene 2013; 514: 36-40.
  
  N-acetylcysteine normalizes the urea cycle and DNA repair in cells from patients with Batten disease. Cell Biochemistry & Function 2012; 30: 677-82.
  
  Normokalemic periodic paralysis is not a distinct disease. Muscle and Nerve 2012; 46: 908-13.
  
  Possible therapeutic effects of myxobacterial metabolites on type I Gaucher disease. Gene 2012; 504: 156-9.
  
  Novel de novo nonsense mutation of FBN1 gene in a patient with Marfan syndrome. Journal of Genetics 2012; 91: 233-5.
  
  Familial hyperkalemic periodic paralysis caused by a de novo mutation in the sodium channel gene SCN4A. Korean Journal of Pediatrics 2011; 54: 470-2.
  
  Altered expression of potassium channel genes in familial hypokalemic periodic paralysis. Neurology Asia 2011; 16: 205-10.
  
  Possible therapeutic effect of growth hormone in Gaucher disease cells. Hormone Research in Paediatrics 2011; 76: S2: 81.
  
  Expression patterns of two potassium channel genes in skeletal muscle cells of patients with familial hypokalemic periodic paralysis. Neurology India 2011; 59: 527-31.
  
  Transient neonatal diabetes mellitus caused by a de novo ABCC8 gene mutation. Korean Journal of Pediatrics 2011; 54: 179-82.
  
  Hyperkalemic periodic paralysis and paramyotonia congenita caused by a de novo mutation in the SCN4A gene. Neurology Asia 2011; 16: 163-6.
  
  A study on the measurement of the nucleated red blood cell (nRBC) count based on birth weight and its correlation with perinatal prognosis in infants with very low birth weights. Korean Journal of Pediatrics 2011; 54: 69-78.
  
  Hematologic profiles and eosinophilia in very low birth weight infants. Korean J Perinatol 2011; 4: 285-94.
  
  A case of neonatal lupus erythematosus and retrospectively diagnosed with asymptomatic maternal Lupus erythematosus. J Korean Soc Neonatol. 2011; 18: 391-4.
  
  Reduced expression and abnormal localization of the KATP channel subunit SUR2A in patients with familial hypokalemic periodic paralysis. Biochemical and Biophysical Research Communications 2010; 391: 974-8.
  
  Expression pattern of Kir6.2 in skeletal muscle cells of patients with familial hypokalemic periodic paralysis. Journal of Life Science 2010; 20: 457-61.
  
  An atypical phenotype of familial hypokalemic periodic paralysis caused by a mutation in the sodium channel gene SCN4A. Korean Journal of Pediatrics 2010; 53: 909-12.
  
  Resveratrol upregulates p21, a cell cycle regulator, in Gaucher disease cells. Journal of Life Science 2010; 20: 1281-6.
  
  Identification of a novel de novo mutation in the SCN4A gene in a patient with paramyotonia congenita. Journal of Neurology 2010; 257: S1: 103.
  
  Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the CACNA1S gene in a patient with hypokalemic periodic paralysis. European Journal of Paediatric Neurology 2010; 14: 278-81.
  
  Effect of extracellular potassium on delayed rectifier potassium channel proteins of KCNQ3 and KCNQ5 in familial hypokalemic periodic paralysis. Journal of Life Science 2009; 19: 1484-8.
  
  The etiology of precocious puberty. Konyang Medical Journal 2009; 9: 59-61.　　
  
  Novel de novo mutation in the KCNJ2 gene in a patient with Andersen-Tawil syndrome. Pediatric Neurology 2009; 41: 464-6.
  
  The genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis. Journal of Korean Medical Science 2007; 22: 946-51.
  
  The effect of gonadotropin releasing hormone agonist with or without growth hormone treatment on predicted adult height in girls with early puberty. Annals of Pediatric Endocrinology & Metabolism 2007; 12: 21-6.
  
  The efficacy of speech and language therapy for children with speech and language delays according to the etiologies. Korean Journal of Pediatrics 2005; 48: 924-8.
  
  A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G). Journal of Korean Medical Science 2005; 20: 162-5.